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INTRODUCTION
Bone marrow transplantation (BMT) represents an effec-
tive treatment for many blood disorders, including acute
myelogenous leukemia (AML) and chronic myelogenous
leukemia (CML) [1,2]. For autologous transplantation, the
primary risk factor is leukemic relapse due to the inefﬁciency
of the patient’s immune system to mount a meaningful
response against residual tumor cells. A better understanding
of potential myeloid leukemia antigens in AML and CML
could enhance the ability to stimulate autologous T-cell
responses, either ex vivo or in vivo. For allogeneic BMT, the
issue of leukemic relapse is still present and further compli-
cated by an inverse relationship between the incidence and
severity of graft-versus-host disease (GVHD) [3-7]. Donor
cell populations responsible for mediating GVHD are also
thought to mediate the graft-versus-leukemia (GVL)
response, thereby reducing the incidence of leukemic relapse.
An important step toward separating GVHD and GVL
responses hinges on finding either tissue-specific or
leukemia-speciﬁc antigens that can be selectively targeted by
donor T-cell populations.
Many tumor-speciﬁc shared antigens have been identi-
ﬁed to date, including those encoded by the MAGE, BAGE,
and GAGE families of genes [8-11]. These antigens are
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ABSTRACT
A c-myc retrovirus–transformed myeloid leukemia line, MMB3.19, of C57BL/6 (B6) origin, was developed to investi-
gate graft-versus-leukemia (GVL) activity in murine bone marrow transplantation (BMT) models. It was previously
determined that both naive and leukemia-presensitized CD4+-enriched T cells are capable of mediating GVL activ-
ity to MMB3.19 challenge in both syngeneic (B6) and allogeneic (C3H.SW→B6) strain combinations, with the lat-
ter coinciding with minimal graft-versus-host disease. In the present study, MMB3.19 and 2 other similarly derived,
yet phenotypically diverse, B6 myeloid leukemia lines (MMB1.10 and MMB2.18) were investigated for potential
shared tumor antigens in the syngeneic GVL model. Morphologically, all 3 tumor lines are blastic with high cyto-
plasmic:nuclear ratios, but MMB2.18 displays dendritic processes, whereas MMB1.10 and MMB3.19 have a more
rounded appearance. Flow cytometric analysis of the 3 lines revealed constitutive surface molecule expression of
Mac-1, Mac-2, F4/80, LFA-1, B7-1, B7-2, H2Kb, H2Db, and macrophage scavenger receptor, consistent with macro-
phage/monocyte lineages. Furthermore, each of the lines expresses H2I-Ab, but to varying degrees, with MMB2.18
cells having the lowest percentage (31.6%). In vitro 51Cr release assays using MMB3.19-primed T-cell effectors
demonstrated equivalent specific lysis of all 3 leukemia-line target cells. In addition, enzyme-linked immunospot
analysis of MMB3.19-primed CD4+ T cells revealed significantly increased frequencies of tumor-stimulated inter-
leukin (IL)-2–, IL-4–, and interferon-–secreting cells when restimulated with each of the 3 leukemia lines.
Furthermore, when MMB3.19-primed CD4+ T cells were administered in a BMT setting, a protective GVL effect
was seen in those mice challenged with MMB1.10, MMB2.18, or MMB3.19. Therefore, in vitro and in vivo experi-
ments indicate that the 3 distinct myeloid leukemia lines share 1 or more common major histocompatibility complex
class II–restricted tumor antigens that can elicit a cross-protective in vivo T-cell GVL response.
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expressed by many melanomas, lung carcinomas, sarcomas,
and bladder carcinomas, but rarely, if ever, by leukemias [12-
14]. In addition, although a tumor-speciﬁc antigen has been
found in a radiation-induced leukemia line [15], and tumor-
speciﬁc cytotoxic T lymphocytes (CTLs) have been shown
to target synthetic bcr-abl leukemia antigens in vitro [16-18],
shared leukemia antigens capable of stimulating GVL
responses in vivo have yet to be described. To date, the clos-
est things to leukemia-restricted antigens that may be of any
value have been minor histocompatibility antigens (mHAs)
(eg, the HA-5 peptide) that are restricted to expression in
hematopoietic tissue, including host leukemia cells [19].
Previously, an allogeneic murine myeloid leukemia BMT
model using a c-myc–transformed myeloid leukemia line,
MMB3.19, was used to study GVL activity in an mHA-mis-
match system [20]. Transformation was achieved in vivo by
injection of a nonreplicating c-myc retrovirus construct,
which randomly integrates the c-myc encoding exons 1 and 2
preferentially into the myeloid lineage and, as such, can
induce tumorigenesis of myeloid leukemias in varying differ-
entiation stages [21,22]. These tumor cells do not produce
any detectable retrovirus product. Therefore, any antigens
that they might express are likely to be a consequence of the
oncogenic process itself, initiated by the overexpression of
c-myc. The unique availability of several myeloid leukemia
lines from the same strain with varying phenotypic origins
allows us to investigate whether common tumor antigens
may be targeted in a GVL response. To address this question,
the syngeneic B6 BMT model was used with the different
myeloid leukemia lines to focus on the speciﬁc antileukemia
response without the added complications of histocompati-
bility differences.
In this report, we analyzed 3 leukemia lines, MMB1.10,
2.18, and 3.19, for morphological differences, surface molecule
expression, cross-stimulatory potential in enzyme-linked
immunospot (ELISPOT) and CTL assays, and cross-protective
ability in GVL survival assays. All 3 tumor lines were found to
be blastic, but with distinct morphology, and to express typical
myeloid markers. 51Cr release assays using MMB3.19-primed
T cells demonstrated equal speciﬁc lysis of all 3 myeloid tumor
lines. Similarly, ELISPOT assays and in vivo GVL survival
experiments demonstrated that MMB3.19-presensitized CD4+
T cells responded to restimulation with and protected against
challenge by MMB1.10, MMB2.18, or MMB3.19, indicating
that the 3 tumor lines share 1 or more common major histo-
compatibility complex (MHC) class II–restricted determinants
capable of eliciting a cross-protective T-cell GVL response.
MATERIALS AND METHODS
Mice
Male H2b C57BL/6J (B6) mice were purchased from the
Jackson Laboratory (Bar Harbor, ME). Donors were
between the ages of 8 and 12 weeks; recipients were between
the ages of 8 and 16 weeks. Mice were housed in a sterile
environment in microisolators and given autoclaved food and
acidiﬁed water ad libitum.
Cell Lines
The 2myc8 cell line produces retroviral particles contain-
ing the pEVX-mycXH RNA construct, which, upon infection,
causes stable integration and expression of the c-myc gene under
the control of the Moloney LTR promoter [23]. Using an
approach described previously [24], 2myc8 supernatant was
injected intraperitoneally (IP) into pristane-primed B6 mice,
several of which after 3 to 6 months developed ascites from
which tumor cells were collected. Tumor clones were then
established by limiting dilution in the presence of irradiated thy-
mocyte feeder cells. The MMB1.10, MMB2.18, and MMB3.19
cloned lines were originally derived from separate mice and
were selected for use in the current investigation on the basis of
their different morphology. Wright-Giemsa staining was used
for microscopic examination of the MMB tumor lines. The B6
methylcholanthrene-induced ﬁbrosarcoma MC57G (ATCC
#CRL-2295) was used as a control transformed cell line in
assays for immune responsiveness and was MHC class I–posi-
tive and class II–negative.
Media
The MMB tumor lines and splenocytes were grown in
RPMI 1640 (Mediatech, Herndon, VA) plus 10% fetal calf
serum (FCS) (Sigma, St. Louis, MO), supplemented with
L-glutamine, penicillin/streptomycin (Mediatech), and 2-mer-
captoethanol (Life Technologies, Grand Island, NY), at 37°C
in 7% CO2. The MC57G line was cultured in Iscove’s (Media-
tech) plus 10% FCS, supplemented with L-glutamine, peni-
cillin/streptomycin, and 2-mercaptoethanol, at 37°C in 7%
CO2. Phosphate-buffered saline (PBS) supplemented with
0.1% bovine serum albumin (BSA) (Sigma) was used for in
vitro manipulation of donor bone marrow cells and lympho-
cytes. Cells were resuspended in PBS alone for all injections
into recipients.
Monoclonal Antibodies
Anti-Thy-1.2 (J1j; rat immunoglobulin [Ig] M) [25], anti-
CD8 (3.168; rat IgM) [26], and anti-NK1.1 (pk136; IgG2a)
[27] monoclonal antibodies (MoAbs) were obtained from
ascites ﬂuid and used with guinea pig C (Rockland,
Boyertown, PA) for cell depletions. Afﬁnity-puriﬁed goat anti-
mouse IgG antibody (Cappel-Organon Teknika, West Chester,
PA) was used for B-cell panning. For phenotypic analysis of the
leukemia lines and donor lymphocyte preparations, ﬂuorescein
isothiocyanate (FITC)-labeled anti-B7-1 (CD80), anti-B7-2
(CD86), anti-H2Kb, anti-H2Db, anti-IAb, anti-CD3, anti-
CD4, anti-CD8, and anti-B220 MoAb (all from PharMingen,
San Diego, CA) and rat anti-mouse macrophage scavenger
receptor (MCA1322) MoAb (Serotec, Oxford, UK) were used.
In addition, anti-Mac-1 (CD11b), anti-Mac-2, anti-F4/80, and
anti-LFA-1 (CD11a) MoAb were used for analysis, as previ-
ously described [24]. For ELISPOT analysis, puriﬁed rat anti-
mouse interleukin (IL)-2 MoAb (clone JES6-1A12; IgG2a)
[28]; IL-4 MoAb (clone BVD4-1D11; IgG2b) [28]; and inter-
feron (IFN)- MoAb (clone R4-6A2; IgG1) [29] were used for
primary cytokine capture. Biotinylated rat anti-mouse IL-2
MoAb (clone JES6-5H4; IgG2b) [30]; IL-4 MoAb (clone
BVD6-24G2; IgG1) [28]; and IFN- MoAb (clone XMG1.2;
IgG1) [29] were used for detection of cytokines. All MoAbs for
the ELISPOT assay were purchased from PharMingen.
Preparation of Cells
Anti-Thy-1–treated (T cell–depleted) bone marrow
(ATBM) was prepared by ﬂushing femurs and tibias of donor
GVL Cross-Protection
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mice and incubating bone marrow cells with J1j MoAb
(1:200 dilution) and C (1:12 dilution) for 45 minutes at
37°C. To obtain T cell–enriched donor populations, spleen
and lymph node cells were treated with red blood cell lysing
solution containing 0.8% NH4Cl and allowed to adhere to
plastic petri dishes coated with 1:200 dilution of goat anti-
mouse IgG for 1 hour at room temperature. The collected
nonadherent T cells were further enriched for the CD4+ sub-
set by treatment with anti-CD8 MoAb (3.168; 1:100 dilu-
tion) and C (1:12 dilution) for 45 minutes at 37°C. CD4+-
enriched T-cell populations contained FITC background
levels of CD8+ T cells (<1%).
Flow Cytometry
For phenotypic analysis of leukemia lines and T-cell–
enriched populations, appropriate FITC-labeled MoAbs in
25 mL were incubated with 2  105 cells in 96-well round-
bottom plates for 30 minutes at 4°C and washed 3 times with
100 mL PBS, 1% BSA, and 0.02% sodium azide. Samples
were then ﬁxed with 1% paraformaldehyde and analyzed for
ﬂuorescence on an EPICS Proﬁle II analyzer (Coulter
Electronics, Hialeah, FL).
CTL Assays
Cross-cytolytic T-cell activity was determined by a
standard 51Cr release assay. T cells were isolated from
MMB3.19-primed mice and restimulated with 1:1 irradiat-
ed (20 Gy) syngeneic splenocytes and 1:100 irradiated
(30 Gy) MMB3.19 tumor cells in RPMI 1640, 10% FCS,
and 1:10 T-Stim culture supplement (Collaborative
Biomedical Products, Bedford, MA) for 5 days at 37°C, 7%
CO2. Directly before the CTL assay, effectors were depleted
of natural killer (NK) cells using anti-NK1.1 MoAb and C.
MMB1.10, MMB2.18, MMB3.19, and MC57G targets were
radiolabeled with 100 µCi Na2
51CrO4 (Amersham, Arlington
Heights, IL) for 1 hour at 37°C, washed, resuspended, and
then added (1  104/well) to the effectors (in triplicate) at
various effector:target (E:T) cell ratios in 96-well U-bottom
plates (Nalge Nunc, Naperville, IL) for 4 hours at 37°C, 7%
CO2. Culture supernatants were harvested and counted in a
LKB-Wallac CliniGamma 1272 automatic  counter (Wallac,
Turku, Finland). Spontaneous release of 51Cr was determined
by incubation of targets in the absence of effectors. Maximal
release was determined by incubation of targets in deter-
gent. Results are expressed as percent speciﬁc lysis, which
was calculated using the following equation: % speciﬁc
lysis = [(experimental – spontaneous)/(maximal – sponta-
neous)]  100.
ELISPOT Assay to Detect Single Cytokine–Secreting
CD4+ T Cells
The frequencies of IL-2–, IL-4–, and IFN-–secreting
CD4+ T cells in MMB3.19-primed mice were determined by
the ELISPOT assay, as described previously [30,31]. Brieﬂy,
CD4+ T cells (1  107 cells/15 mL) were isolated as
described above from mice that were presensitized 2 to
3 weeks before with irradiated (30 Gy) MMB3.19 cells (5 
106, IP). Then they were incubated with syngeneic irradiat-
ed (20 Gy) splenocytes (1  107) in the presence or absence
of irradiated (30 Gy) MMB1.10, MMB2.18, MMB3.19, or
control MC57G cells (1  105) for 48 hours at 37°C, 7%
CO2. The splenocytes were included as a source of MHC
class II–positive antigen-presenting cells for optimum stimu-
lation of responses to tumor-derived antigens.
Nitrocellulose-backed microtiter plates (Millipore, Bedford,
MA) were coated overnight at 4°C with cytokine-speciﬁc
primary capture MoAbs, including puriﬁed rat anti-mouse
IL-2 (50 µg/mL), IL-4 (25 µg/mL), or IFN- (50 µg/mL)
MoAb in a ﬁnal volume of 50 mL coating buffer (borate
buffer, pH 8.5, 0.1 mol/L). Plates were then washed and
blocked, and 1 to 2  106 cultured cells were added in tripli-
cate and incubated overnight at 37°C, 7% CO2. After exten-
sive washing, spot-forming IL-2–, IL-4–, or IFN-–secret-
ing cells were detected by addition of 50 µL/well biotin-
labeled cytokine-specific secondary detecting MoAbs,
including biotin rat anti-mouse IL-2 (2 µg/mL), IL-4 (0.33
µg/mL), and IFN- (4 µg/mL) MoAb. The plates were then
washed and developed using alkaline phosphatase–labeled
streptavidin (Southern Biotechnologies, Birmingham, AL)
and 50 mL of Sigma FAST BCIB/NBT (5-bromo-4-chloro-
3-indolyl phosphate/nitro blue tetrazolium). Development
was stopped by washing with deionized water.
Survival Assay for GVL Activity
B6 mice were lethally irradiated with 9.5 Gy (from a
Shepherd Mark-I-68A 137Cs source; 1.43 Gy/min) and 4 to
6 hours later were intravenously injected with a syngeneic
donor inoculum of 2  106 ATBM cells, alone or including
T cells (2  106). Donor T cells were either unfractionated
or enriched for the CD4+ subset. They were from mice that
were either naive or presensitized 2 to 3 weeks previously
with irradiated (30 Gy) MMB3.19 cells (5  106, IP).
Recipients were challenged 1 day later with MMB1.10,
MMB2.18, or MMB3.19 cells (0.5 to 2  105 cells, IP in
0.5 mL PBS). Mice were checked daily for morbidity and
mortality until the termination of experiments. The non-
parametric Wilcoxon signed rank test was used for statistical
comparisons of survival curves.
RESULTS
Morphological and Phenotypic Comparison of 
MMB Cell Lines
Morphologic analysis of the MMB1.10, MMB2.18, and
MMB3.19 cell lines revealed that all 3 tumors were blastic,
with a high cytoplasmic:nuclear ratio (Figure 1). A high pro-
portion of MMB2.18 cells exhibited extensive dendritic-like
cytoplasmic processes (Figure 1B), whereas MMB1.10
(Figure 1A) and MMB3.19 (Figure 1C) cells were more
rounded in appearance. In culture, MMB1.10 and MMB3.19
grew more rapidly (doubling time approximately 15.7 hours)
than MMB2.18 cells (doubling time approximately 19.4 hours).
In regard to adherence characteristics, MMB3.19 cultures
contained the highest percentage of nonadherent cells
(approximately 72%), compared with 12% to 14% in the
other 2 lines (data not shown). Next, the MMB tumor lines
were analyzed by ﬂow cytometry for phenotypic expression of
various myeloid-related determinants. All 3 lines contained a
high percentage (>75%) of cells expressing Mac-1, Mac-2,
F4/80, B7-1, B7-2, H2Kb, H2Db, and macrophage scavenger
receptor (Table). In addition, although all 3 lines also
expressed H2I-Ab and LFA-1, MMB1.10 and MMB3.19 cells
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did so to a greater degree (>80% positive for both markers)
than did MMB2.18 (31.6% and 65.8%, respectively). These
morphological and phenotypic results, in addition to consid-
eration of the tumorigenic strategy used for their generation
[21,22], determined that the MMB cell lines were all of the
macrophage/monocyte lineage, but with distinct features.
Cross-Lytic Potential of MMB3.19-Primed CTL
To determine whether CTL effectors can recognize
common determinants expressed by the myeloid tumor lines,
B6 mice were presensitized IP with irradiated (30 Gy)
MMB3.19 (2 to 3 weeks), and lymph node and spleen T cells
were isolated and restimulated in vitro for 5 days in the pres-
ence of irradiated (20 Gy) syngeneic splenocytes and irradi-
ated (30 Gy) MMB3.19 cells. These CTL effectors were
then depleted of NK cells (by treatment with anti-NK1.1
MoAb and C) and tested for the ability to lyse MMB1.10,
MMB2.18, MMB3.19, and MC57G (a control B6 line) tar-
get cells. MMB3.19-primed T cells mediated equivalent spe-
ciﬁc lysis (45% to 50% at 27:1 E:T ratio) of all 3 MMB tar-
get cells at levels well above that of MC57G cells (Figure 2).
This cross-lytic potential was titratable and was still evident
at the 3:1 E:T ratio.
Cytokine Production of Cross-Reactive 
Anti-MMB T Cells
Having determined that the 3 MMB lines share 1 or
more common targetable antigens using unfractionated
T-cell cytolytic effectors, we investigated whether these lines
also expressed 1 or more common antigens capable of cross-
stimulating cytokine production by CD4+ T cells. This issue
was of particular importance because CD4+ T cells had pre-
viously been demonstrated to mediate GVL responses in the
absence of GVHD in both syngeneic and allogeneic
MMB3.19 models [20]. ELISPOT assays were thus used to
detect the frequency of IL-2–, IL-4– and IFN-–producing
CD4+ T cells from MMB3.19-presensitized B6 mice, after in
vitro restimulation with each irradiated MMB line (a 2-day
Figure 2. Cross-cytolytic potential of MMB3.19-primed unfractionated
T cells in 4-hour 51Cr release assays. MMB3.19-primed T cells were
restimulated in vitro with irradiated (30 Gy) MMB3.19 cells and irradi-
ated (20 Gy) splenocytes for 5 days and depleted of natural killer cells
before incubation with radiolabeled target cells at the effector:target cell
ratios shown. Data are expressed as the mean % speciﬁc lysis ± SE and
are representative of 2 similar experiments. CTL indicates cytotoxic
T lymphocyte.
Flow Cytometric Phenotypic Analysis of Myeloid Cell Lines*
Cell Expression, %
Antibody specificity MMB1.10 MMB2.18 MMB3.19
FITC control IgG 0.8 1.3 1.3
B7-1 (CD80) 90.0 95.8 95.3
B7-2 (CD86) 100.0 98.0 99.8
H2Kb 96.2 96.6 99.0
H2Db 77.2 85.5 86.9
H2I-Ab 89.8 31.6 81.5
FITC control IgG 0.3 0.3 0.7
Mac-1 (CD11b) 99.1 96.2 83.9
Mac-2 99.7 98.9 99.3
F4/80 85.0 94.7 95.0
LFA-1 (CD11a) 92.5 65.8 90.3
Macrophage scavenger receptor 99.6 81.1 99.9
*FITC indicates ﬂuorescein isothiocyanate; Ig, immunoglobulin.
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incubation in the presence of irradiated B6 splenocytes). A
high frequency of IL-2–producing cells, indicated by elevat-
ed numbers of spots/well, was observed when each of the
MMB lines was present in the restimulation cultures, but not
in the absence of the tumor cells (Figure 3A). In a similar
manner, high frequencies of IL-4– and IFN-–producing
CD4+ T cells were present in cultures restimulated with each
of the 3 MMB lines, but not in those restimulated with the
control MC57G cell line (Figure 3B), suggesting that the
anti-MMB response is speciﬁc for determinants expressed by
these myeloid lines. Interestingly, cytokines associated with
both helper type 1 (IFN-) and type 2 (IL-4) were signiﬁ-
cantly elevated in the responding antileukemic populations.
Cross-Protective GVL Responses
Based on the in vitro data suggesting that the 3 MMB lines
shared a common immunogenic antigen, BMT-GVL assays
were performed to investigate whether this cross-reactivity
translated into cross-protective in vivo GVL responses. Donor
B6 mice were presensitized with irradiated (30 Gy) MMB3.19
cells 2 to 3 weeks before spleen and lymph node harvest.
Donor lymphocytes were T-cell enriched, and 2  106
MMB3.19-primed or naive T cells were injected intravenous-
ly into lethally irradiated (9.5 Gy) recipient mice along with 2
 106 ATBM. Mice receiving 2  106 MMB3.19-primed
T cells and rechallenged 1 day later with 1  105 MMB3.19
cells exhibited full long-term protection (80% survival; P ≤
.04) compared with those mice receiving either no T cells
(MMB3.19 group) or naive T cells, which succumbed by day
37 with median survival times (MSTs) of 23 and 34 days,
respectively (Figure 4C). Similarly, mice receiving the same
dosage of MMB3.19-primed T cells and a subsequent chal-
lenge of 1  105 MMB1.10 cells had signiﬁcantly prolonged
survival (MST 56 days; P ≤ .04) over those receiving either no
T cells or naive T cells (MST 22 and 35 days, respectively)
(Figure 4A). However, such a cross-protective beneﬁt was not
observed in mice challenged with 1  105 MMB2.18 cells
(Figure 4B). Groups receiving either MMB3.19-primed or
naive T cells experienced similar GVL responses to MMB2.18
leukemia challenge (P ≥ .07), with MST 47 days.
Because MMB3.19-primed CD4+ T cells were capable of
responding by cytokine production to restimulation with all
3 MMB lines in the ELISPOT assays, the GVL survival
studies were repeated using MMB3.19-primed or naive
CD4+ T cells. As with unfractionated T cells, 2  106 CD4+-
enriched MMB3.19-primed T cells mediated protection
against challenge with either MMB1.10 or MMB3.19 cells
(MST 21 and 26 days, respectively) (Figures 5A and 5C). For
both of these leukemia challenges, mice given the primed
CD4+ T cells experienced signiﬁcantly prolonged survival
(P ≤ .01) over those receiving naive CD4+ T cells (MST 18
and 21 days, respectively). Mice challenged with MMB2.18
cells also displayed a signiﬁcant, albeit far less impressive,
benefit from transplantation of MMB3.19-primed CD4+
T cells compared with those receiving naive donor cells
(MST 67 versus 59 days; P ≤ .03) (Figure 5B).
To further accentuate the protective effect of MMB3.19-
primed CD4+ T cells, syngeneic BMT B6 recipients were
challenged with half the number of MMB1.10 and 3.19 cells
(5  104). The pattern of cross-protection was readily appar-
ent in the mice challenged with MMB1.10 cells (MST 28 ver-
sus 19 days for the naive T-cell inoculum; P ≤ .04) (Figure
6A). Mice challenged with MMB3.19 cells and transplanted
with primed CD4+ T cells exhibited enhanced survival over
that previously observed (40% versus 0% by day 50) (Figure
6B versus Figure 5C) and over the mice given the naive T-cell
inoculum (MST 37 versus 24 days; P ≤ .04) (Figure 6B).
Figure 3. Cross-stimulatory potential of the MMB lines as determined
by enzyme-linked immunospot (ELISPOT) assays. MMB3.19-primed
CD4+ T cells were restimulated with irradiated (20 Gy) splenocytes ±
irradiated (30 Gy) MMB tumors or MC57G for 48 hours and analyzed
in interleukin (IL)-2 (A) or IL-4 and interferon (IFN)- (B) ELISPOT
assays. Results are expressed as the number of spots/well + SE, and the
data are representative of 2 similar experiments. *SE ≤1.2 spots/well.
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To further enhance the weak MMB2.18 GVL response,
the donor CD4+ T-cell dosage was doubled (4  106) along
with the reduction in tumor challenge (5  104). In addition,
a group of mice that received MMB2.18-primed CD4+
T cells was included to gauge the maximum expected GVL
potential. An enhanced level of GVL protection (P < .03) was
observed in the groups given either MMB2.18- or
MMB3.19-presensitized CD4+ T cells (MST 58 and 55 days,
respectively) over mice given naive CD4+ T cells (MST 40
days) (Figure 7). The GVL responses between the direct and
cross-primed groups were equivalent (P > .67), suggesting
that the latter antigens were sufﬁcient to generate the maxi-
mum effect.
DISCUSSION
Although allogeneic BMT is now recognized as a cura-
tive treatment for AML and CML, leukemic relapse remains
a major risk factor for patients. The fact that leukemic
relapse still poses such a threat can be attributed in part to
the lack of knowledge about myeloid leukemia antigens. It
has yet to be determined whether common leukemia-speciﬁc
antigens exist and can be selectively targeted by GVL-reac-
tive cells to enhance antileukemic responses in the setting of
allogeneic BMT. Uenaka et al. [15] have identiﬁed a radia-
tion leukemia tumor antigen, and others have demonstrated
that tumor-speciﬁc CTLs can target proteinase 3 [32] and
bcr-abl junctional peptides [16-18] in vitro. Furthermore, in
Figure 4. Cross-protective graft-versus-leukemia capacity of MMB3.19-primed unfractionated T cells upon in vivo challenge with the 3 MMB
tumor lines. Lethally irradiated recipient B6 mice were injected intravenously with 2  106 donor anti-Thy-1–treated (T cell–depleted) bone mar-
row (ATBM) cells alone or in addition to MMB3.19-primed or naive donor T cells (2  106). One day later, mice were challenged with 1  105
MMB1.10 (A), MMB2.18 (B), or MMB3.19 (C) cells intraperitoneally in 0.5 mL phosphate-buffered saline (n = 5 for all groups). P values represent
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vivo cross-protective immunity has been demonstrated in a
subset of tumors derived from murine fetal ﬁbroblasts [33].
However, shared leukemia antigens capable of stimulating
cross-protective CTL responses in vivo have yet to be
described.
In this report, we studied 3 distinct c-myc–derived myelo-
genous leukemia lines, originating from different B6 mice, to
investigate potential shared tumor antigens. These leukemia
lines are relevant because they are derived from a common
transforming oncogene (as are many human tumors); express
no detectable retroviral particles; have undergone secondary,
spontaneous genetic alterations; and are of the myeloid lineage
(expressing Mac-1, Mac-2, F4/80, LFA-1, and macrophage
scavenger receptor). These leukemia lines are similar to spon-
taneous tumors in that they express an activated form of the
normal mouse c-myc gene and are thought to have undergone
secondary spontaneous mutations necessary for conversion to
metastatic tumors [21,22].
In allogeneic BMT, a signiﬁcant portion of the GVL
response may be due to reactivity to allogeneic differences,
both MHC and mHA, expressed by residual leukemia cells.
In the setting of HLA-matched allogeneic GVL, the relative
contributions of mHA-reactive and leukemia-speciﬁc anti-
gen–reactive T cells are unknown. Others have demonstrat-
ed the existence of mHA-driven GVL responses [34-37].
However, in the current study, to address the possibility of
Figure 5. Cross-protective graft-versus-leukemia effect of MMB3.19-primed CD4+ T cells upon challenge with the 3 MMB tumor lines. Lethally
irradiated recipient B6 mice were injected intravenously with 2  106 donor anti-Thy-1–treated (T cell–depleted) bone marrow (ATBM) cells alone
or in addition to MMB3.19-primed or naive CD4+ T cells (2  106). One day later, mice were challenged with 1  105 MMB1.10 (A), MMB2.18 (B),
or MMB3.19 (C) cells intraperitoneally in 0.5 mL phosphate-buffered saline. All groups contained 10 mice (pooled from 2 similar experiments), and
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leukemia-speciﬁc antigens shared by similarly derived yet
phenotypically distinct myeloid tumor lines, attention was
focused on a syngeneic murine BMT model to eliminate any
allogeneic contributions to the GVL response. The ﬁndings
demonstrate that all 3 of the myeloid leukemia lines tested
possess 1 or more common leukemia-speciﬁc antigens and are
capable of cross-immunizing. MMB3.19-primed T-cell popu-
lations (unfractionated or CD4+) exhibited reactivity to all 3
tumor lines in both in vitro assays (ELISPOT and 51Cr release
cytolysis) and in vivo GVL survival assays. Interestingly,
although in vitro experiments indicated equivalent MMB3.19-
primed antitumor responses against MMB1.10 and MMB2.18
stimulators, an in vivo cross-protective GVL effect against
MMB2.18 challenge was far less evident than the effect
against MMB1.10 challenge (Figures 4 and 5). Anti-
MMB2.18 responses became more evident when increased
numbers of CD4+ T cells and a lower tumor burden were
used in the model. In general, there may be several factors
responsible for such a difference in GVL activity, including
fewer shared antigens (or lower expression levels) on
MMB2.18 cells, differential antigen-presenting capabilities
or costimulatory potential of the tumor cells, or varying
production of inhibitory cytokines. Concerning antigen
stimulation capacity, CD4+ T cells from B6 mice presensi-
tized in vivo with irradiated MMB1.10, MMB2.18, or
MMB3.19 cells proliferated in vitro equivalently upon res-
timulation with each of the tumor lines, demonstrating that
all lines were potentially cross-stimulatory (data not shown).
In addition, semiquantitative reverse transcription–poly-
merase chain reaction analysis determined that all 3 MMB
lines exhibited a similar pattern of messenger RNA (mRNA)
expression of inhibitory cytokines—ie, tumor necrosis factor
(TNF)-+, IL-10+, and transforming growth factor-– (data
not shown)—suggesting that they were unlikely to be
responsible for the lower level of protection against
MMB2.18 challenge. Furthermore, ELISPOT analysis of
MMB3.19-primed CD4+ T cells revealed similar patterns of
T helper 1 (IFN-) and T helper 2 (IL-4) cytokine produc-
tion when restimulated with each of the 3 tumor lines
(Figure 3), suggesting that a differential skewing of the
immune response is not a likely reason for the difference in
GVL potency against MMB2.18.
An important role for CD4+ T cells in GVL responses
has been demonstrated in clinical studies, particularly in the
case of CML [38], and is supported by similar ﬁndings in
murine models [20,39-41]. CD4+ T cells likely mediate GVL
effects indirectly by providing cytokine help to CD8+ T cell,
NK cell, and other inﬂammatory cell effectors, or directly via
cytotoxicity mechanisms that include perforin/granzyme
release, TNF- release, or Fas/FasL interactions [42-44].
For 2 of the MMB tumors used in the current study
(MMB1.10 and MMB3.19), it has recently been demonstrat-
ed that CD4+ T cells can effectively use both a perforin and
FasL-mediated cytolytic mechanism to resist tumor growth
Figure 6. Cross-protective graft-versus-leukemia effect of MMB3.19-primed CD4+ T cells against a lower tumor burden. Lethally irradiated recip-
ient B6 mice were injected intravenously with 2  106 donor anti-Thy-1–treated (T cell–depleted) bone marrow (ATBM) cells alone or in addition
to MMB3.19-primed or naive CD4+ T cells (2  106). One day later, mice were challenged with 5  104 MMB1.10 (A) or MMB3.19 (B) cells
intraperitoneally in 0.5 mL phosphate-buffered saline (n = 5 for all groups). P values represent signiﬁcance between groups receiving primed versus
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[45,46]. Yet, despite the GVL potential of CD4+ T cells, few
MHC class II–restricted leukemia antigens have been found
to date [47,48], perhaps largely because of the relative difﬁ-
culty in developing CD4+ antitumor T-cell lines. Therefore,
efforts must be made to fully appreciate the scope of these
responses and to exploit the advantages of this antileukemic
immune component.
Given that autologous and syngeneic grafts can be manip-
ulated to mediate GVL effects with and without a concomi-
tant, autoimmune-like GVHD, it is probable that tumor-spe-
cific (non–allogeneic-based) antigens do exist [49-52].
However, it is not certain whether antigens representing
overexpressed, normally occurring antigens or truly novel
antigens arising from unique secondary mutations are respon-
sible for these tumor-speciﬁc responses. An example of an
overexpressed normal self-protein found in myeloid leukemia
cells is proteinase-3 [32], whereas examples of novel mutated
genes in leukemia include t(9;22) in CML and t(15;17),
t(8;21), and inv16 in AML [53-56]. MMB leukemia lines
probably contain overexpressed normal proteins due to the
presence of cross-immunogenic determinants and the
method of development (introduction of c-myc, a potent tran-
scription factor). In regard to this possibility, syngeneic
transplants using MMB3.19-primed T cells exhibit no overt
pathology as evidence of an autoimmune-like reaction
(recipients have normal weight gain, posture, coat appear-
ance, activity level). In addition, 51Cr release assays using
MMB3.19-primed CTL effectors revealed speciﬁc lysis of
MMB3.19 cells but no signiﬁcant lysis of either B6 con-
canavalin A or lipopolysaccharide blasts, suggesting that the
target antigens were not ubiquitously expressed on other
hematopoietic cells. However, we have not ruled out the
possibility that novel mutations have given rise to targetable
determinants. Our model of myeloid leukemia cross-protec-
tion is an important ﬁrst step in further elucidating the exis-
tence of shared tumor-speciﬁc antigens. Further studies in
this system will enable us to characterize the shared deter-
minants present in these distinct, oncogenically derived
myeloid leukemia lines.
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